Surgery

2019/04/09MEDICAL UPDATE

Translational science in IBD

Translational research is playing an increasingly vital role for bridging the gap between, on the one hand, basic science and on the other, clinical studies and routine clinical practice. Among the findings presented in a digital oral presentation session at ECCO 2019 were new insights into the mechanism of action of vedolizumab and potential new therapeutic targets for treating fibrosis and strictures in IBD...

READ MORE

2019/04/09MEDICAL UPDATE

IBD around the world

IBD is still mainly a phenomenon of the Western world, but the incidence is increasing steeply in newly industrialised countries where the population is undergoing rapid urbanisation...

READ MORE

2019/03/13MEDICAL UPDATE

Metabolic profiling

Metabolic interactions between the gut microbiome and its human host are thought to play a key role in the development of IBD and may hold the key to finding new disease markers and targets for intervention.

READ MORE

2019/03/13MEDICAL UPDATE

VARSITY: head to head comparison of adalimumab vs vedolizumab in UC

The first-ever head-to-head comparative trial of two biological therapies in IBD indicates that UC patients treated with vedolizumab are significantly more likely to achieve remission than with adalimumab. More head-to-head trials are due to be completed shortly and the results are expected to be as important for clinical practice as the SONIC, CALM and NOR-SWITCH studies.

READ MORE

2019/03/11MEDICAL UPDATE

ECCO 2019 Highlights

The sessions at ECCO 2019 were packed full of interesting data highlights and hot topics relevant to the treatment of IBD. In the video above, Professor Stefan Schreiber (Germany), Professor David Rubin (USA), Dr Filip Baert (Belgium) and Professor William Sandborn (USA) discuss their highlights from the meeting including the long-awaited head to head VARSITY study comparing adalimumab with vedolizumab and the maintenance data from the UNIFI study for ustekinumab. 

READ MORE

2018/12/05MEDICAL UPDATE

Advanced Stage Disease

As survival with frontline chemotherapy has steadily improved for patients with advanced Hodgkin lymphoma several studies have looked at how far short- and long-term toxicity can be reduced without loss of effect. Experts presented updates on three of the landmark studies …

READ MORE

2018/03/01MEDICAL UPDATE

ECCO 2018: Evolving concepts of IBD pathogenesis

By Maria Dalby (articles) and Peter Mas Mollinedo (interviews) Perianal fistula is a debilitating complication in CD which affects up to 50% of patients in the course of their disease...

READ MORE

2017/10/30MEDICAL UPDATE

ESCP 2017: Innovation in fistula management: sections and high-precision removal of the fistula epithelium 

by Maria Dalby Effective treatment options for perianal fistulas constitute a major unmet need in Crohn’sdisease (CD). New interventions included a knot-free silicon drain to replace conventional setons, and a circular blade that allows high-precision removal of the fistula epithelium prior to reparative surgery.

READ MORE

2017/10/11MEDICAL UPDATE

ESCP 2017: Multidisciplinary decision-making for colectomy: the difficult patient 

By Maria Dalby (article) and Peter Mas Mollinedo (interviews) The decision to perform a colectomy in patients with ulcerative colitis (UC) should not be made lightly. Such a decision should always be made within a multi-disciplinary team setting, and surgery should be considered not only for patients who are refractory to medical therapy or who need surgery, but also for…

READ MORE

2017/10/03MEDICAL UPDATE

ESCP 2017: Innovations in fistula management: stem cell therapy

By Maria Dalby (article) and Peter Mas Mollinedo (interviews) In an overview of the immunological rationale for, and clinical application of adipose-derived mesenchymal stem cell (MSC) therapies, Dr Nick Powell  predicted that clinicians treating patients with perianal CD are going to be early uptakers of these therapies as they transition into clinical practice.

READ MORE